Since most benefits were observed in PD-L1-positive patients, it is reasonable to suggest that PD-1/PD-L1 can be a promising biomarker to predict breast cancer responsiveness to PD-1/PD-L1 checkpoint blockade. The gene discussed is PDCD1; the disease is breast cancer.